BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:NTQ1062 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of NTQ1062\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07393321-9073@assetmemo.bio
DTSTAMP:20261121T005855Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:NTQ1062: Phase 3 readout est. (NCT07393321)
DESCRIPTION:NTQ1062\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStudy:
  A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for
  the Treatment of Advanced or Metastatic HR+/HER2- Breast Cancer\nEstimate
 d primary completion: 31 August 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/ntq1062#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07393321
URL:https://assetmemo.bio/drug/ntq1062#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
